研究单位：[1]Boehringer Ingelheim[2]Tongji Hospital, Tongji University Shanghai, China, 200065[3]First Affiliated Hospital of Xi'an JiaoTong University Xi'an, China, 710061[4]General Hospital of Ningxia Medical University Yinchuan, China, 750004[5]CEQUIN Armenia, Colombia, 55860[6]Corazon IPS S.A.S.Barranquilla, Colombia, 0000[7]Clínica de la Costa Ltda. Barranquilla, Colombia, 0[8]General Hospital Karlovac Karlovac, Croatia, 47000[9]Hospital for Medical Rehabilitation, Krapinske Toplice Krapinske Toplice, Croatia, 49217[10]General Hospital Slavonski Brod Slavonski Brod, Croatia, 35000[11]General Hosp. Zadar, Dept. of Internal Medicine-Pulmonology Zadar, Croatia, 23000[12]Harrisburg Family Medical Center Harrisburg, Arkansas, United States, 72432[13]Cardiology and Medicine Clinic Little Rock, Arkansas, United States, 72204[14]Little Rock Diagnostic Clinic Little Rock, Arkansas, United States, 72205[15]Kaiser Permanente - San Diego, Bonita Bonita, California, United States, 91902[16]John Muir Physician Network Clinical Research Center Concord, California, United States, 94520[17]Valley Research Fresno, California, United States, 93720[18]VA Loma Linda Healthcare System Loma Linda, California, United States, 92357[19]Long Beach Center for Clinical Research Long Beach, California, United States, 90807[20]Clearview Medical Research, LLC Los Angeles, California, United States, 90019[21]National Research Institute Los Angeles, California, United States, 90057[22]Office of Dr. Richard S. Cherlin Los Gatos, California, United States, 95032[23]Coastal Medical Research Group Los Osos, California, United States, 93402
研究目的：
The aim of the study is to investigate the longterm impact on cardiovascular morbidity, mortality and renal function of treatment with linagliptin in a selected population of patients with Type 2 diabetes mellitus (T2DM) and to compare outcomes against placebo, on a background of standard of care
